An observational study in Covid-19, Health Personnel and Personnel, Hospital, sponsored by Nordsjaellands Hospital. Completed at 2 sites in Denmark. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Nordsjaellands Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in COVID-19 with a site in Denmark — 10 open to participants now, 12 under way, 3 of them phase 3. COVID-19 · Denmark.
Among the 99 studies in COVID-19 with a site in Denmark, this one is the 24th largest by enrollment of the 43 observational ones that give a count, is one of 55 that started in 2020, is one of 43 observational ones, and was the 22nd registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →10 of the 99 studies in COVID-19 with a site in Denmark are open now. Recruiting first, the newest first:
Pfizer · Sites in Denmark, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Denmark, United States, Argentina and 16 more countries
Ages 12+
Hvidovre University Hospital · Sites in Denmark
Ages 18+ · Healthy volunteers
AstraZeneca · Sites in Denmark, United States, Argentina and 36 more countries
Ages 18+
Ditte Gertz Mogensen · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 26 · Phase 4 6
First in 2017; this study’s year is marked. 55 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 317 across the 55 interventional studies, 417 across the 43 observational. Of the 70 that completed or were terminated, 20 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 99 have an industry lead sponsor. The 10 most frequent:
Nordsjaellands Hospital is the lead sponsor of 89 studies on the registry; 19 are open to participants now.
Nordsjaellands Hospital has 4 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
3 of the studies in COVID-19 with a site in Denmark that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 99 studies in COVID-19 with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to apply serology testing methods for SARS-CoV2 antibodies in samples collected from HCWs in an acute hospital. This will enable the identification of those who are protected and non-infectious for SARS-CoV2 and those who are seronegative and therefore potentially susceptible and infectious on patient contact. Prospective testing will provide data on the acquisition of SARS-CoV2 infections among HCWs and associated risk factors for transmission during a pandemic at an acute care hospital facility in the capital region of Denmark.
Hypothesis: Serial seroconversion measurements in hospital employees improve the organization of the clinical treatment and care during the COVID-19 pandemic at Nordsjællands Hospital and Nykøbing Falster County Hospital.
The study is a prospective cohort study. Weekly (in the first phase) and bi-weekly (in the second phase) serum samples will be drawn and shipped bi-weekly to laboratory collaborators in United Kingdom for antibody analyses during the course of the local epidemic, expected to last 10-12 weeks or more. After the cease of the epidemic serum will be drawn in 3-monthly intervals in a smaller group of seroconverted volunteers to follow the long-lasting immunity of SARS-CoV-2 infection up to 5 years post-pandemic.
Nurses, medical doctors, biomedical laboratory scientists, social health care assistants, and few healthcare administrators (as controls) will be invited for enrolment. In hospitals, all departments with staff that are in physical contact with patients during the pandemic will be invited to participate in the study.
Health care workers at two Danish hospitals
Inclusion Criteria: hospital employee
-
Exclusion Criteria: none
Serial seroconversion measurements in hospital employees during the COVID-19 pandemic
Other: Serial seroconversion measurements in hospital employees during the COVID-19 pandemic
The aim of this study is to apply serology testing methods for SARS-CoV2 antibodies in samples collected from HCWs in an acute hospital.
Serology testing for specific COVID-19
IgM and IgG (Covid-19 antibodies)
Time frame: From baseline to follow up at four years
SARS-CoV-2 infection
Swab, SARS-CoV-2
Time frame: From baseline to follow up at three months
Co-variates
Age, gender, employment details, smoking, chronic diseases
Time frame: At baseline
Ran from Mar 2020 to primary completion in Sep 2023, 41 months.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 41 months is above that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Aug 2025 → Sep 2023 and completion Aug 2025 → Sep 2023.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nordsjaellands Hospital